#NEWS: We have acquired Nerio Therapeutics. Why? Their knowledge will help us to fight cancer by activating our own immune system. Learn more on why we have added their small molecule checkpoint inhibitor to our oncology pipeline: https://lnkd.in/e9i3SdqY #Cancer #ImmunoOncology #ResearchAndDevelopment
Boehringer Ingelheim
Arzneimittelherstellung
Ingelheim am Rhein, Rhineland-Palatinate 1.817.185 Follower:innen
Info
Unsere Mitarbeitenden sind unsere Stärke. Gemeinsam mit über 53.000 Kolleg*innen schaffen wir den nächsten Durchbruch: neue Innovationen für die Gesundheit von Menschen und Tieren.
- Website
-
http://www.boehringer-ingelheim.com
Externer Link zu Boehringer Ingelheim
- Branche
- Arzneimittelherstellung
- Größe
- 10.001+ Beschäftigte
- Hauptsitz
- Ingelheim am Rhein, Rhineland-Palatinate
- Art
- Privatunternehmen
- Spezialgebiete
- Pharmaceuticals, Animal Health, Innovation, Research, Health Care, Improve Health, Biopharmaceuticals und Contract Manufacturing
Orte
Beschäftigte von Boehringer Ingelheim
-
Gwen Whitfield Foster
-
Thomas Macauley
Research Data Management - Lab Services Engineer at Boehringer-Ingelheim
-
Mitchell Taub
Highly Distinguished Research Fellow
-
Ralf Schundelmeier
Product Leader (ex Salesforce) - Building Platforms for Applications, GenAI / Machine Learning & Data
Updates
-
#NEWS: The European Committee for Medicinal Products for Human Use (CHMP) recommends approval of new and expanded indications for our generalized pustular psoriasis (#GPP) treatment option. Learn more here: https://lnkd.in/eCXSSm_E #Dermatology
-
Early and confident detection of disease progression is crucial for people living with fibrosing lung disease. Through our partnership with Brainomix, we want to help revolutionize the diagnostic landscape and thereby enable earlier treatment decisions. Learn more about the partnership below.
Brainomix and Boehringer Ingelheim Launch Strategic Partnership in Fibrosing Lung Disease The project will evaluate the real-world impact of Brainomix's e-Lung imaging software to improve the identification and access to treatment for people with progressive pulmonary fibrosis in the US. Michalis Papadakis: "There is an urgent need to improve the identification of people with fibrosing lung disease. This will enable earlier access to specialist care and the opportunity for faster initiation of treatment, which can slow the worsening of the disease. The patient pathway for people with fibrosing lung disease is currently fragmented and it can take many years for a patient to be diagnosed. "This partnership enables us to leverage our established experience and expertise connecting stroke networks to develop a similar network model of care for patients with fibrosing lung disease, generating real-world evidence that will drive the opportunities we have with e-Lung to help improve outcomes for patients and their families." Read more about this partnership: ⬇ https://lnkd.in/eFhtvQhE Boehringer Ingelheim #eLung #ai #fibrosinglungdisease #BI #partnership #USA #lung #Brainomix360
-
#NEWS: In the first half of 2024, our pipeline has advanced significantly across our key therapy areas. We’ve increased our R&D investment, accelerating our launch readiness. Read more about our key performance figures as well as an outlook on our innovation efforts:
-
United, we are unstoppable. We're taking a significant step towards addressing the global impact of cardiovascular, renal, and metabolic conditions. By sponsoring the innovative CKMH Initiative from the American Heart Association, we're helping to fill gaps in clinical care and support early, holistic treatment. #LifeForward
A third of U.S. adults are at high risk for CKM syndrome, but many patients receive fragmented care. Today we are proud to launch an initiative to change that with American College of Physicians, American Diabetes Association, American Society of Nephrology, National Kidney Foundation, STOP Obesity Alliance at The George Washington University- Milken Institute School of Public Health and Cardiometabolic Center Alliance. Over the next four years, the Cardiovascular-Kidney-Metabolic Health Initiative will work to implement a person-centered approach to awareness, professional and patient education, and treatment of #CKMSyndrome. #cardiology #nephrology
-
#NEWS: Over a billion people worldwide are affected by cardiovascular, renal, and metabolic conditions. We're taking action by supporting the CKMH Initiative from the American Heart Association. This effort aims to address clinical care gaps and foster the development of comprehensive treatment guidelines. Learn more here: https://bit.ly/3zKXd8x #LifeForward
-
How can research and development improve patient outcomes across cardiovascular, renal, and metabolic diseases? This is just one of the topics our panel of global experts discussed at EASL | The Home of Hepatology Learn more: https://lnkd.in/e5wCiXD9 #LiverHealth #LifeForward
-
When a patient was diagnosed with schizophrenia, one of his immediate concerns was the stigma he might face – even from doctors. “If you visit a physician and mention you live with schizophrenia, and then ask for help with a physical pain, the doctor will question whether the pain is real or not,” he explains. His experience is unfortunately not unique. For people with serious mental health conditions, stigma remains a big barrier in receiving the care they need. How can we help change it? Read more here: https://bit.ly/3XILu4l
-
By embracing diversity in #ClinicalTrials, we enable more equitable and inclusive healthcare. How can this be achieved? Swipe right to learn more.
-
We're not only driving innovation ourselves, we're also sharing open source technologies and device development knowledge with others. In order to improve retinal health monitoring we're sharing our software and to best involve patients in device development we provide our blueprint. Want to know more about our approach? Explore here: https://bit.ly/3XicGXt #PatientCentricity #HealthcareInnovation #KnowledgeSharing